Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter

PurposeGemcitabine and vinorelbine have demonstrated clinical efficacy both as single agents and in combination in patients with metastatic non-small cell lung cancer (NSCLC). This phase II trial evaluated biweekly gemcitabine and vinorelbine in NSCLC patients who have had one prior chemotherapeutic regimen and have had disease progression.MethodsGemcitabine (1,200 mg/m2 IV over 30 min) was followed by vinorelbine (30 mg/m2 IV over 6–10 min) on …